Clinical Trials Logo

Mesothelioma, Malignant clinical trials

View clinical trials related to Mesothelioma, Malignant.

Filter by:

NCT ID: NCT06031636 Recruiting - Clinical trials for Malignant Pleural Mesothelioma, Advanced

Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma

Start date: July 20, 2023
Phase:
Study type: Observational

The purpose of this study is to evaluate the efficacy and safety of Oncolytic Adenovirus(H101) combined with PD-1 inhibitor in patients with advanced malignant pleural mesothelioma who have previously been resistant to advanced PD-1 inhibitors.

NCT ID: NCT05960773 Recruiting - Mesothelioma Clinical Trials

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

Start date: January 31, 2024
Phase: Phase 2
Study type: Interventional

This is a Phase II study to determine the rate of stabilization or disease improvement from investigational decitabine/cedazuridine (INQOVI) treatment in subjects with BRCA1-Associated Protein-1 (BAP1) Cancer Predisposition Syndrome (CPDS) and subclinical, early-stage mesothelioma. Progression-free survival (PFS) will also be determined for treated subjects, and the treatment safety (toxicity) evaluated.

NCT ID: NCT05944237 Recruiting - Neoplasms Clinical Trials

HTL0039732 in Participants With Advanced Solid Tumours

Start date: July 13, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this trial is to evaluate a new drug, HTL0039732, that will be administered on its own (as a monotherapy) and in combination with atezolizumab or with other approved anti-cancer therapies, in participants with advanced solid tumours.

NCT ID: NCT05930665 Recruiting - Clinical trials for Pleural Mesothelioma

Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma

Start date: November 1, 2023
Phase: Phase 2
Study type: Interventional

Cadonilimab, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile of the combination therapy. The aim of this study is to evaluate the efficacy and safety of cadonilimab in combination with bevacizumab and standard chemotherapy as first Line therapy in unresectable pleural mesothelioma.

NCT ID: NCT05795595 Recruiting - Clinical trials for Pancreatic Adenocarcinoma

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

Start date: March 13, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors.

NCT ID: NCT05765084 Recruiting - Clinical trials for Malignant Pleural Mesothelioma

Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma

Immuno-MESODEC
Start date: February 24, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

In this multicenter phase I/II trial, the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab and dendritic cells (DCs) loaded with the mesothelioma-associated tumor antigen WT1 will be integrated into platinum/pemetrexed-based first-line chemotherapy for the treatment of epitheloid malignant pleural mesothelioma (MPM). The general objective is to provide the first-in-human experimental demonstration that the combination of platinum/pemetrexed-based chemotherapy with atezolizumab and WT1/DC vaccination is feasible and safe, has clinical activity and enables the induction of mesothelioma-specific immune responses in patients with MPM.

NCT ID: NCT05730816 Recruiting - Mesothelioma Clinical Trials

MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI

MAGIC-AKI
Start date: April 4, 2023
Phase: Phase 2
Study type: Interventional

In this research study, investigators will test whether prophylactic high-dose IV Mg administration attenuates the risk of AKI in patients with malignant mesothelioma receiving intraoperative chemotherapy (HIOC) with cisplatin compared to placebo .

NCT ID: NCT05703854 Recruiting - Clinical trials for Advanced Renal Cell Carcinoma

Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

Start date: March 29, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

To find a recommended dose of donated NK cells that can be given with lymphodepleting chemotherapy to patients with advanced renal cell carcinoma, mesothelioma, or osteosarcoma. The effects of this therapy will also be studied.

NCT ID: NCT05660616 Recruiting - Clinical trials for Malignant Pleural Mesothelioma

Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma

Start date: April 1, 2023
Phase: Phase 2
Study type: Interventional

Mesothelioma is an aggressive form of cancer. Treatments are available, but for many people, a cure isn't possible. This thesis is to assess the efficacy and safety of switch-maintenance Gemcitabine in Mesothelioma patients after first line chemotherapy (Pemetrexed-Platinum)

NCT ID: NCT05655078 Recruiting - Clinical trials for Malignant Pleural Mesothelioma

Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma

HIT-Meso
Start date: March 28, 2024
Phase: N/A
Study type: Interventional

Phase III randomised-controlled trial for patients with unilateral malignant pleural mesothelioma (MPM).